AXSM
NASDAQAxsome Therapeutics Inc.
Price$185.69+3.76 (+2.07%)
01:30 PM07:45 PM
News · 26 weeks63+1000%
2025-10-262026-04-19
Mix3590d
- Insider17(49%)
- SEC Filings7(20%)
- Other6(17%)
- Earnings3(9%)
- Analyst1(3%)
- M&A1(3%)
Latest news
25 items- SECSEC Form DEFA14A filed by Axsome Therapeutics Inc.DEFA14A - Axsome Therapeutics, Inc. (0001579428) (Filer)
- SECSEC Form DEF 14A filed by Axsome Therapeutics Inc.DEF 14A - Axsome Therapeutics, Inc. (0001579428) (Filer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Jacobson Mark L.4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Tabuteau Herriot4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERChief Commercial Officer Maizel Ari exercised 7,500 shares at a strike of $70.73 and sold $1,368,150 worth of shares (7,500 units at $182.42) as part of a pre-agreed trading plan (SEC Form 4)4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Maizel Ari4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Pizzie Nick4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERSEC Form 4 filed by General Counsel Murdock Hunter R.4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- PRAxsome Therapeutics to Report First Quarter 2026 Financial Results on May 4NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2026 on Monday, May 4, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presentation
- SECAxsome Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)
- PRAxsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric ConditionsAxsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitor Acquisition further expands Axsome's industry-leading CNS portfolio with a novel mechanism for neuropsychiatric conditions NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063 (balipodect), a novel, oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor from Takeda. Axsome intends to develop the select
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Axsome Therapeutics Inc.SCHEDULE 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)
- INSIDERSEC Form 4 filed by Chief Executive Officer Tabuteau Herriot4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERSEC Form 4 filed by General Counsel Murdock Hunter R.4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Maizel Ari4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Jacobson Mark L.4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Pizzie Nick4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERChief Operating Officer Jacobson Mark L. exercised 35,378 shares at a strike of $2.85 and sold $5,726,991 worth of shares (35,378 units at $161.88) (SEC Form 4)4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- INSIDERDirector Coleman Mark sold $4,027,750 worth of shares (25,000 units at $161.11), decreasing direct ownership by 35% to 47,140 units (SEC Form 4)4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- PRPsychedelic Medicine Advances: Here Are Five Companies Targeting CNS DisordersIssued on behalf of Helus PharmaVANCOUVER, BC, Feb. 26, 2026 /CNW/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that milestone this week, signaling a potential shift in how regulators and investors view psychedelic-based psychiatry[1]. The pathway is widening at the federal level, where the Drug Enforcement Administration raised its 2026 psilocybin production quota by 67%[2]. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), Relmada Therapeutics (NASDAQ:RLMD), Alto Neuroscience (NYSE:ANRO), and Axsome
- INSIDERDirector Coleman Mark exercised 6,250 shares at a strike of $4.95, increasing direct ownership by 9% to 72,140 units (SEC Form 4)4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
- PRAxsome Therapeutics to Participate in Upcoming Investor ConferencesNEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care ConferenceFireside Chat: Monday, March 2, 2026, at 3:10 p.m. ET in Boston, MA Leerink Partners Global Healthcare ConferenceFireside Chat: Monday, March 9, 2026, at 4:20 p.m. ET in Miami Beach, FL The Citizens Life Sciences ConferenceFireside Chat: Tuesday, March 10, 2026, at 4:00 p.m. ET in Miami Beach, FL UBS Biotech Summit Miami – Catalyst for ChangeInvestor Meetings:
- ANALYSTWolfe Research initiated coverage on Axsome Therapeutics with a new price targetWolfe Research initiated coverage of Axsome Therapeutics with a rating of Outperform and set a new price target of $230.00
- PRAxsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness SymptomsNEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the CLARITY Phase 3 trial of solriamfetol in the treatment of major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms. CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with MDD with EDS symptoms consisting of an open-label solriamfetol treatment period and
- INSIDERDirector Coleman Mark exercised 12,485 shares at a strike of $4.95, increasing direct ownership by 23% to 65,890 units (SEC Form 4)4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)